- Home
- DRVN vs DYN Comparison
DRVN vs DYN Comparison
Compare DRVN & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRVN
- DYN
- Stock Information
- Founded
- DRVN 1972
- DYN 1984
- Country
- DRVN United States
- DYN United States
- Employees
- DRVN N/A
- DYN N/A
- Industry
- DRVN Automotive Aftermarket
- DYN Medicinal Chemicals and Botanical Products
- Sector
- DRVN Consumer Discretionary
- DYN Health Care
- Exchange
- DRVN Nasdaq
- DYN Nasdaq
- Market Cap
- DRVN 2.7B
- DYN 848.8M
- IPO Year
- DRVN 2021
- DYN 2020
- Fundamental
- Price
- DRVN $18.08
- DYN $11.30
- Analyst Decision
- DRVN Buy
- DYN Strong Buy
- Analyst Count
- DRVN 10
- DYN 12
- Target Price
- DRVN $20.00
- DYN $47.73
- AVG Volume (30 Days)
- DRVN 677.1K
- DYN 2.7M
- Earning Date
- DRVN 05-06-2025
- DYN 05-08-2025
- Dividend Yield
- DRVN N/A
- DYN N/A
- EPS Growth
- DRVN N/A
- DYN N/A
- EPS
- DRVN N/A
- DYN N/A
- Revenue
- DRVN $2,373,759,000.00
- DYN N/A
- Revenue This Year
- DRVN N/A
- DYN N/A
- Revenue Next Year
- DRVN $8.89
- DYN N/A
- P/E Ratio
- DRVN N/A
- DYN N/A
- Revenue Growth
- DRVN 2.59
- DYN N/A
- 52 Week Low
- DRVN $10.59
- DYN $6.36
- 52 Week High
- DRVN $18.01
- DYN $47.45
- Technical
- Relative Strength Index (RSI)
- DRVN 64.23
- DYN 55.04
- Support Level
- DRVN $16.11
- DYN $9.17
- Resistance Level
- DRVN $18.72
- DYN $12.47
- Average True Range (ATR)
- DRVN 0.56
- DYN 1.02
- MACD
- DRVN 0.24
- DYN 0.12
- Stochastic Oscillator
- DRVN 79.45
- DYN 73.65
About DRVN Driven Brands Holdings Inc.
Driven Brands Holdings Inc is an automotive services company in North America. Its platform provides high-quality services to an extensive range of retail and commercial customers. The company provides an extensive range of core consumer and commercial automotive needs, including paint, collision, glass, and repair services, as well as a variety of high-frequency services, such as oil changes and car washes.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.